Symbols

BBIO

BridgeBio Pharma·NASDAQ

--(--)

Signals Analysis

Bullish signal 5

Bearish signal 1

Stock Price Surged Significantly

Consensus Rating "Buy"

Ample Liquidity

High Gross Profit Margin

Gap Up

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About BBIO

Bridgebio Pharma, Inc.

A commercial-stage biopharmaceutical company focused on genetic diseases and cancers

Industry

Biological Technology

Established Date

05/17/2019

Listing Date

06/27/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

834

Fiscal Year Ends

12-31

Website

www.bridgebio.com

Security Type

Common stock

Office address

3160 Porter Drive, Suite 250, Palo Alto, CA 94304

Business

Introduction

BridgeBio Pharma, Inc., was incorporated in Delaware on May 17, 2019. The Company is a commercial-stage biopharmaceutical company that aims to discover, create, test and deliver transformative medicines to treat patients with hereditary diseases and cancers with clear genetic drivers.

Company Financials

EPS

BBIO has released its 2025 Q4 earnings. EPS was reported at -1, versus the expected -0.72, missing expectations. The chart below visualizes how BBIO has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

BBIO has released its 2025 Q4 earnings report, with revenue of 154.18M, reflecting a YoY change of 2521.18%, and net profit of -194.63M, showing a YoY change of 27.21%. The Sankey diagram below clearly presents BBIO's revenue sources and cost distribution.